Back to
Dr Joanne Carson

Dr Joanne Carson

Research Associate
  • Doctor of Philosophy (Medicine/Data Science)

University of New South Wales | Sydney, Australia | 2023

 

  • Master of Public Health (Biostatistics/Epidemiology)

Curtin University | Perth, Australia | 2018

  • Bachelor of Science (Pharmacology/Immunology)

University of New South Wales | Sydney, Australia | 2012

Medicine & Health
The Kirby Institute

Joanne Carson is an interdisciplinary Health informatician, data scientist and infectious disease researcher interested in pharmacoepidemiology, big-data analytics, artificial intelligence and data engineering. She is an Associate Member of the International Centre for Future Health Systems.

 
E-mail
jcarson@kirby.unsw.edu.au
  • Journal articles | 2025
    Harney BL; Sacks-Davis R; van Santen DK; Stewart AC; Matthews GV; Carson JM; Klein MB; Lacombe K; Wittkop L; Salmon D; Leleux O; Merchadou L; van der Valk M; Smit C; Prins M; Boyd A; Berenguer J; Jarrin I; Rauch A; Hellard ME; Doyle JS, 2025, 'Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort', Liver International, 45, pp. 1 - 13, http://dx.doi.org/10.1111/liv.16203
    Journal articles | 2024
    Griffin S; Lee Wilkinson A; Winter R; Hajarizadeh B; MacIsaac M; Papaluca T; Holmes J; Lloyd AR; Carson J; Craigie A; Hellard M; Stoové M; Thompson A, 2024, 'Contribution of prison-based hepatitis C treatment initiations to overall treatment uptake in Victoria, Australia', The Lancet Regional Health - Western Pacific, 48, http://dx.doi.org/10.1016/j.lanwpc.2024.101139
    Journal articles | 2024
    Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ, 2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895
    Journal articles | 2024
    Martinello M; Carson JM; Post JJ; Finlayson R; Baker D; Read P; Shaw D; Bloch M; Doyle J; Hellard M; Filep E; Hosseini-Hooshyar S; Dore GJ; Matthews GV, 2024, 'Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014-2023)', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofae665
    Journal articles | 2024
    Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M; Ke T; Zhang Y; Pedrana A; Asselin J; Dawe J; Wilkinson A; Schinkel J; Sogni P; Esterle L; Gilbert C; Merchadou L; Gillet S; Khan C; Le Marec F; Perrier A; Shaw I; Martinello M; Applegate T; Carson J; Harney B; Bryant M; Jarrin Vera I; Alejos B; Lazarus JV; Moreno C; Izquierdo R; Rava M; Wang S; Lumia J; Pexos C; Peiris H; Saeed S; Moodie E; Pick N; Conway B; Hull M; Wong A; Gill J; Barrett L; Cohen J; Cox J; Cote P; Haider S; Rouleau D; Vachon ML; Rachlis A; Sandre R; Walmsley S; Sadr A; Cooper C; Sanche S; Salazar-Viscaya L; Kusejko K; Hage K; Requena MB; Girard PM; Brucker M; Vincensini JP, 2024, 'Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies', The Lancet HIV, 11, pp. e106 - e116, http://dx.doi.org/10.1016/S2352-3018(23)00267-9
    Journal articles | 2024
    van Santen DK; Stewart A; Doyle JS; Stoové MA; Asselin J; Klein MB; Young J; Berenguer J; Jarrin I; Lacombe K; Wittkop L; Leleux O; Salmon D; Bonnet F; Rauch A; Mugglin C; Matthews G; Prins M; Smit C; Boyd A; van der Valk M; Sacks-Davis R; Hellard ME, 2024, 'Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)', International Journal of Epidemiology, 53, http://dx.doi.org/10.1093/ije/dyad154
    Journal articles | 2023
    Beiser ME; Shaw LC; Shores SK; Carson JM; Hajarizadeh B, 2023, 'Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston', Clinical Infectious Diseases, 77, pp. 46 - 55, http://dx.doi.org/10.1093/cid/ciad127
    Journal articles | 2023
    Carson J; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016-2021', Hepatology Communications, 7, pp. e0125, http://dx.doi.org/10.1097/HC9.0000000000000125
    Journal articles | 2023
    Carson JM; Barbieri S; Cunningham E; Mao E; van der Valk M; Rockstroh JK; Hellard M; Kim A; Bhagani S; Feld JJ; Gane E; Thurnheer MC; Bruneau J; Tu E; Dore GJ; Matthews GV; Martinello M, 2023, 'Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study', Journal of the International AIDS Society, 26, pp. e26168, http://dx.doi.org/10.1002/jia2.26168
    Journal articles | 2023
    Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'Corrigendum to ‘National trends in retreatment of HCV due to reinfection or treatment failure in Australia’ (J Hepatol [2023] 260–270) (Journal of Hepatology (2023) 78(2) (260–270), (S016882782203118X), (10.1016/j.jhep.2022.09.011))', Journal of Hepatology, 78, pp. 1084, http://dx.doi.org/10.1016/j.jhep.2023.02.020
    Journal articles | 2023
    Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia', Journal of Hepatology, 78, pp. 260 - 270, http://dx.doi.org/10.1016/j.jhep.2022.09.011
    Journal articles | 2023
    Hage K; van de Kerkhof M; Boyd A; Carson JM; Newsum AM; Matser A; van der Valk M; Brinkman K; Arends JE; Lauw FN; Rijnders BJA; van Eeden A; Martinello M; Matthews GV; Schinkel J; Prins M, 2023, 'Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study', Pathogens, 12, pp. 1248, http://dx.doi.org/10.3390/pathogens12101248
    Journal articles | 2023
    Jessica HB; Carson J; Scott M; Patricia C; Nelson R; Helen VG; Phillip R; Hanson J; Robert M; Matthews G; Dore GJ; Martinello M; Read P, 2023, 'Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C)', Journal of Viral Hepatitis, 30, pp. 386 - 396, http://dx.doi.org/10.1111/jvh.13803
    Journal articles | 2023
    Martinello M; Carson JM; Van Der Valk M; Rockstroh JK; Ingiliz P; Hellard M; Nelson M; Lutz T; Bhagani S; Kim AY; Hull M; Cordes C; Moon J; Feld JJ; Gane E; Rauch A; Bruneau J; Tu E; Applegate T; Grebely J; Dore GJ; Matthews GV, 2023, 'Reinfection incidence and risk among people treated for recent hepatitis C virus infection', AIDS, 37, pp. 1883 - 1890, http://dx.doi.org/10.1097/QAD.0000000000003651
    Journal articles | 2023
    Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon JA; Lloyd AR; Dore GJ; Wiseman V; Grebely J, 2023, 'Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis', The Lancet Regional Health - Western Pacific, 36, http://dx.doi.org/10.1016/j.lanwpc.2023.100750
    Journal articles | 2022
    Bartlett SR; Verich A; Carson J; Hosseini-Hooshyar S; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Martinez M; Marks P; Dore GJ; Matthews GV; Applegate T; Martinello M; Hosseini Hooshyar S, 2022, 'Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort', Health Science Reports, 5, http://dx.doi.org/10.1002/hsr2.719
    Journal articles | 2022
    Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B, 2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246
    Journal articles | 2022
    Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Matthews GV; Dore GJ; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Stewart J; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort', Journal of Viral Hepatitis, 29, pp. 661 - 676, http://dx.doi.org/10.1111/jvh.13705
    Journal articles | 2022
    Yee J; Carson JM; Hajarizadeh B; Hanson J; O’Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV; Hanson J; Marks P; Byrne M; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Davies J; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study', Hepatology Communications, 6, pp. 496 - 512, http://dx.doi.org/10.1002/hep4.1826
    Journal articles | 2021
    Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Dore GJ; Matthews GV, 2021, 'Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103422
    Journal articles | 2020
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV, 2020, 'Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV', AIDS, 34, pp. 1347 - 1358, http://dx.doi.org/10.1097/QAD.0000000000002562
  • Reports | 2024
    Carson J; Hajarizadeh B; Dore G, 2024, Monitoring hepatitis C treatment uptake in Australia: Issue #14, July 2024, Kirby Institute, UNSW, Sydney, 14, http://dx.doi.org/10.26190/unsworks/30340, https://www.kirby.unsw.edu.au/research/reports/monitoring-hepatitis-c-treatment-uptake-australia-issue-14-july-2024
    Reports | 2023
    Hajarizadeh B; Carson J; Dore G, 2023, Monitoring hepatitis C treatment uptake in Australia: Issue #13, July 2023, The Kirby Institute, UNSW, Sydney, Australia, http://dx.doi.org/10.26190/81wp-fr56, https://www.kirby.unsw.edu.au/research/reports/monitoring-hepatitis-c-treatment-uptake-australia-issue-13-july-2023
    Conference Abstracts | 2022
    Carson J; Dore G; Lloyd A; Grebely J; Byrne M; Cunningham EB; Amin J; Vickerman P; Martin N; Treloar C; Matthews G; Hajarizadeh B, 2022, 'Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study', in Journal of Hepatology, Elsevier BV, Vol. 77, pp. S565 - S565, http://dx.doi.org/10.1016/s0168-8278(22)01451-9
    Conference Papers | 2021
    Finlayson R; Carson J; Tan L, 2021, 'Tolerability and antiviral activity of bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) treatment switch in patients aged 55 years or older with HIV: the BIO study', in HIV MEDICINE, WILEY, pp. 95 - 96, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000711388200103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Preprints |
    Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267510
    Preprints |
    Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267527

New South Wales Ministry of Health Grant Award: REACH-B-TX sub-study (2024; AUD $107,396.170)

2024

Kirby Institute Emerging Investigator Award

 2023

University of New South Wales Dean’s Award for Outstanding Thesis 

 2023

Elsevier Atlas Award Winner Theme Sustainable Development Goal (SDG3), Good Health and Well-Being Publication

 2023

Kirby Institute Post-Graduate Student Prize

 2022     

Top Ranked Abstract in Clinical Research- International Network on Hepatitis in Substance Users Conference, Glasgow, UK

 2022

Best presentation by STAToSPHERE conference, Sydney Australia
   

Leads the Pharmaco-AI Infectious Disease Surveillance (PHASE) project aiming to enhance capabilities to monitor infectious disease trends, health outcomes and health system utilisation in Australia. PHASE harnesses recent advances in national data-linkage and artificial intelligence to develop novel analytic approaches and advanced pharmacoepidemiologic surveillance systems.